Compare GXO Logistics Inc (GXO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs Organon & Co. Common Stock — how do they compare? GXO Logistics Inc trades at $45.88 (market cap $5.33B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: GXO Logistics Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 29 Days and Organon & Co. Common Stock for 0 Days on average.
| GXO | OGN | |
|---|---|---|
Market Cap | $5.33B | $3.62B |
Volume | 961,023 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $65.59 | $13.81 |
52-Week Low | $44.17 | $5.70 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $10.68B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $46.50, down 0.21% with neutral technical signals. The company shows strong revenue growth with 2026 revenue reaching $13.6B and net profit margin improving to 0.96%. Recent earnings beats and strategic partnerships in Europe and aerospace sectors demonstrate operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and a $66.67 price target, representing 43% upside potential from current levels.
The stock presents compelling value with attractive valuation metrics including P/S of 0.39x, though elevated P/E of 41.15x reflects growth expectations. Key risks include margin pressure from new business at lower incremental margins and competitive industry dynamics. The improving freight industry outlook and GXO's market leadership position support long-term growth prospects despite near-term execution challenges.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
